1. Pregnant or lactating women.2. Patients with a history of thromboembolic disease in the last 3 to 6 months.3. Patient with pre-existing cardiovascular diseases.4. Patients with pre-existing renal failure, or undergoing treatment with extracorporeal clearance methods prior to SARS-CoV-2 infection.5. Patients with pre-existing lung sequelae (including pulmonary fibrosis, COPD, severe asthma, lung cancer, etc.).6. Patients with confirmed serious or life-limiting chronic disease.7. Known hypersensitivity to any of the components of the formulation under study.8. Subject that they are receiving another product under investigation.9. Patients with obvious mental incapacity to give consent and act accordingly with the study.

1. Pregnant or lactating women.2. Patients with a history of thromboembolic disease in the last 3 to 6 months.3. Patient with pre-existing cardiovascular diseases.4. Patients with pre-existing renal failure, or undergoing treatment with extracorporeal clearance methods prior to SARS-CoV-2 infection.5. Patients with pre-existing lung sequelae (including pulmonary fibrosis, COPD, severe asthma, lung cancer, etc.).6. Patients with confirmed serious or life-limiting chronic disease.7. Known hypersensitivity to any of the components of the formulation under study.8. Subject that they are receiving another product under investigation.9. Patients with obvious mental incapacity to give consent and act accordingly with the study.

1. Pregnant or lactating women.2. Patients with a history of thromboembolic disease in the last 3 to 6 months.3. Patient with known cardiovascular diseases that have moderate to severe repercussions of their disease.4. Patients with renal failure undergoing treatment with extracorporeal clearance methods prior to SARS-CoV-2 infection.5. Patients with criteria for potentially serious infection.6. Known hypersensitivity to any of the components of the formulation under study.7. Subject that they are receiving another product under investigation.8. Patients with obvious mental incapacity to give consent and act accordingly with the study.

1. Pregnant or lactating women.2. Patients with a history of thromboembolic disease in the last 3 to 6 months.3. Patient with known cardiovascular diseases that have moderate to severe repercussions of their disease.4. Patients with renal failure undergoing treatment with extracorporeal clearance methods prior to SARS-CoV-2 infection.5. Patients with criteria for potentially serious infection.6. Known hypersensitivity to any of the components of the formulation under study.7. Subject that they are receiving another product under investigation.8. Patients with obvious mental incapacity to give consent and act accordingly with the study.